Table 2.
Regimens of cetuximab-containing chemotherapies in each ESMO guideline group
| Regimens | Group 1 | Group 2 | Group 3 | P valuea |
|---|---|---|---|---|
| Total (N = 562) | 165 (100%) | 224 (100%) | 173 (100%) | |
| Oxaliplatin based (65.7%) | 115 (69.7%) | 147 (65.6%) | 107 (61.8%) | 0.1937 |
| FOLFOX+Cmab | 94 (57.0%) | 116 (51.8%) | 63 (36.4%) | 0.0006 |
| SOX+Cmab | 12 (6.4%) | 21 (9.2%) | 29 (16.7%) | 0.0103 |
| Cape+Cmab | 9 (8.7%) | 10 (5.2%) | 15 (8.6%) | 0.2887 |
| Irinotecan based (30.1%) | 44 (26.7%) | 64 (28.4%) | 61 (35.6%) | 0.1437 |
| FOLFIRI+Cmab | 33 (20.3%) | 54 (24.0%) | 36 (21.3%) | 0.6512 |
| IRIS+Cmab | 10 (5.8%) | 6 (2.6%) | 19 (10.9%) | 0.0026 |
| IRI+Cmab | 1 (0.6%) | 3 (1.3%) | 6 (3.4%) | 0.1352 |
| IFL+Cmab | 0 | 1 (0.4%) | 0 | |
| Cmab monotherapy (3.6%) | 6 (3.5%) | 10 (4.4%) | 4 (2.9%) | 0.6271 |
| Others+Cmab Combinations | 0 | 3 (1.3%) | 1 (0.6%) |
Cape, capecitabine; Cmab, Cetuximab; ESMO, European Society for Medical Oncology; SOX, TS-1 and oxaliplatin.
aBy two-tailed Fisher’s exact test.